Epidemiological and clinical evaluation of hepatitis B, hepatitis C, and delta hepatitis viruses in

[Guest guest]

J Med Virol. 2008 Feb;80(2):268-76.

Epidemiological and clinical evaluation of hepatitis B, hepatitis C, and delta

hepatitis viruses in Tajikistan.

Khan A, Kurbanov F, Tanaka Y, Elkady A, Sugiyama M, Dustov A, Mizokami M.

Department of Clinical Molecular Informative Medicine, Nagoya City University

Graduate School of Medical Sciences, Kawasumi, Mizuho, Nagoya, Japan.

The implication of genotypes is recognized increasingly in the clinical course

of hepatitis B virus (HBV) and in response to anti-viral drugs of hepatitis C

virus (HCV). Genotypic prevalence of both etiological agents varies

geographically and no data are available for Tajikistan. To investigate the

epidemiology and clinical significance of HBV and HCV genotypes in chronic

hepatitis (group 1) and liver cirrhosis/hepatocellular carcinoma (HCC) (group 2)

patients in Tajikistan, 124 patients with chronic liver disease (group 1 = 84

and group 2 = 40) were enrolled. Genotypes of HBV, HCV, and delta hepatitis

virus (HDV) were determined by sequencing. The overall prevalence of anti-HCV,

HCV core antigen (HCVcAg) and HBsAg was 46% (57/124) and 41.1% (51/124),

respectively. Coinfection of HCV/HBV, HBV/HDV, and HCV/HBV/HDV was found in 4.8%

(6/124), 11.2% (12/124), and 0.8% (1/124) of cases, respectively. HDV genotype 1

was found in 19.6% (10/51) of HBsAg-positive patients. The HBV/HDV coinfection

was relatively high in group 2 compared to group 1 (15% vs. 7.1%). HCV/1b

detected in 84.6% (44/52) of HCV RNA-positive patients, followed by 3a (7.6%),

2a (5.7%), and 2c (1.9%). HBV/D was detected in 94.1% (48/51) of HBsAg-positive

patients, followed by HBV/A [5.8% (3/51)]. T1762/A1764 double mutation was

associated with liver cirrhosis/HCC in HBV-infected patients (P = 0.0004). This

is the first study on the molecular epidemiology of hepatitis viruses among

chronic liver diseases patients in Tajikistan. Among HBV-infected patients, the

T1762/A1764 mutation was associated with liver cirrhosis/HCC. J. Med. Virol.

80:268-276, 2008. © 2007 Wiley-Liss, Inc.

PMID: 18098133 [PubMed - in process]

_________________________________________________________________

The best games are on Xbox 360. Click here for a special offer on an Xbox 360

Console.

http://www.xbox.com/en-US/hardware/wheretobuy/

[Guest guest]

J Med Virol. 2008 Feb;80(2):268-76.

Epidemiological and clinical evaluation of hepatitis B, hepatitis C, and delta

hepatitis viruses in Tajikistan.

Khan A, Kurbanov F, Tanaka Y, Elkady A, Sugiyama M, Dustov A, Mizokami M.

Department of Clinical Molecular Informative Medicine, Nagoya City University

Graduate School of Medical Sciences, Kawasumi, Mizuho, Nagoya, Japan.

The implication of genotypes is recognized increasingly in the clinical course

of hepatitis B virus (HBV) and in response to anti-viral drugs of hepatitis C

virus (HCV). Genotypic prevalence of both etiological agents varies

geographically and no data are available for Tajikistan. To investigate the

epidemiology and clinical significance of HBV and HCV genotypes in chronic

hepatitis (group 1) and liver cirrhosis/hepatocellular carcinoma (HCC) (group 2)

patients in Tajikistan, 124 patients with chronic liver disease (group 1 = 84

and group 2 = 40) were enrolled. Genotypes of HBV, HCV, and delta hepatitis

virus (HDV) were determined by sequencing. The overall prevalence of anti-HCV,

HCV core antigen (HCVcAg) and HBsAg was 46% (57/124) and 41.1% (51/124),

respectively. Coinfection of HCV/HBV, HBV/HDV, and HCV/HBV/HDV was found in 4.8%

(6/124), 11.2% (12/124), and 0.8% (1/124) of cases, respectively. HDV genotype 1

was found in 19.6% (10/51) of HBsAg-positive patients. The HBV/HDV coinfection

was relatively high in group 2 compared to group 1 (15% vs. 7.1%). HCV/1b

detected in 84.6% (44/52) of HCV RNA-positive patients, followed by 3a (7.6%),

2a (5.7%), and 2c (1.9%). HBV/D was detected in 94.1% (48/51) of HBsAg-positive

patients, followed by HBV/A [5.8% (3/51)]. T1762/A1764 double mutation was

associated with liver cirrhosis/HCC in HBV-infected patients (P = 0.0004). This

is the first study on the molecular epidemiology of hepatitis viruses among

chronic liver diseases patients in Tajikistan. Among HBV-infected patients, the

T1762/A1764 mutation was associated with liver cirrhosis/HCC. J. Med. Virol.

80:268-276, 2008. © 2007 Wiley-Liss, Inc.

PMID: 18098133 [PubMed - in process]

_________________________________________________________________

The best games are on Xbox 360. Click here for a special offer on an Xbox 360

Console.

http://www.xbox.com/en-US/hardware/wheretobuy/